Peptide Immunotherapy for Peanut Allergy Is Safe and Modulates Immune Response — Phase 1 Trial | Research

The takeaway

PVX108, a seven-peptide immunotherapy targeting T-cell epitopes of major peanut allergens, was safe and well-tolerated in peanut-allergic adults and shifted immune responses away from allergic Th2 cells — with durable effects at 18 months.

Zero allergic reactions
PVX108 peptide immunotherapy was safe in peanut-allergic adults with only mild injection site reactions

What the researchers found

PVX108 peptide immunotherapy was safe in peanut-allergic adults with no hypersensitivity events, and produced durable peanut-specific T-cell modulation (decreased ST2+ Th2A:CCR6+ Th17-like ratio) persisting to 18 months.

Why it matters

Peanut allergy has no cure, and current immunotherapy carries significant risk. Peptide-based immunotherapy that's safe enough to avoid allergic reactions while still reprogramming the immune system could transform food allergy treatment for millions of patients worldwide.

The numbers in context

7 short peptides representing immunodominant T-cell epitopes of major peanut allergens; Phase 1 safety trial.

How the study worked

First-in-human, randomized, double-blind, placebo-controlled Phase 1 trial. Single and repeat doses in peanut-allergic adults (46 active, 21 placebo). Safety and tolerability assessed; exploratory immunological analyses at pre-dose, Week 21, and Month 18.

Who was studied

Patients with peanut allergy

What this study cannot tell us

Phase 1 trial — safety and immune modulation shown, but clinical efficacy (food challenge outcomes) not yet demonstrated. Small sample size. No food challenge performed. Translation from immune biomarker changes to clinical protection needs Phase 2 confirmation.

How to read the evidence

Preliminary evidence — Phase 1 safety and immunogenicity trial. Encouraging safety and immune data but clinical efficacy not yet demonstrated.

When this study was published

Published in 2024. Phase 2 efficacy trials are ongoing.

The bigger picture

Peptide immunotherapy represents a paradigm shift in allergy treatment — from risky whole-allergen exposure to precision immune reprogramming with specific peptide epitopes. Success in food allergy could pave the way for similar approaches in other allergic diseases.

Questions still open

Will the immune modulation seen in Phase 1 translate to protection during peanut food challenges in Phase 2?
Can this peptide approach be extended to other food allergies (tree nut, milk, egg)?
How long does immune tolerance last after a full treatment course — will boosters be needed?

Common questions

Could there be a safe allergy shot for peanut allergy?

PVX108 is the closest we've come. Unlike current peanut immunotherapy (which uses whole peanut protein and can cause severe reactions), PVX108 uses seven tiny peptide fragments that can't trigger allergic reactions but can still teach the immune system to tolerate peanut. In this Phase 1 trial, nobody had an allergic reaction.

Would this treatment cure peanut allergy?

That's the goal, but we don't know yet. This Phase 1 trial showed that PVX108 safely reprogrammed immune cells away from the allergic response, and these changes lasted 18 months. But whether this translates to safely eating peanut is being tested in Phase 2 trials — results are pending.

Read the original research

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Allergy, 79(2), 485-498

View on PubMed ↗Publisher’s paper ↗

Citation

Voskamp, Astrid L; Khosa, Sugandhika; Phan, Tracy; DeBerg, Hannah A; Bingham, Judy; Hew, Mark; Smith, William; Abramovitch, Jodie; Rolland, Jennifer M; Moyle, Matthew; Nadeau, Kari C; Lack, Gideon; Larché, Mark; Wambre, Erik; O'Hehir, Robyn E; Hickey, Pascal; Prickett, Sara R. (2024). Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.. Allergy, 79(2), 485-498. https://doi.org/10.1111/all.15966